Swedish research-based biopharma company BioArctic AB (Nasdaq Stockholm: BIOA B) announced on Thursday that its Japanese partner Eisai has completed the rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lecanemab-irmb (US brand name: Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.
Lecanemab-irmb is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
The BLA is based on data from the Clarity AD open-label extension study and modelling of observed data. If the application is approved by the FDA, the Leqembi autoinjector could be used to administer Leqembi at home or at medical facilities, with the injection process taking approximately 15 seconds on average.
Lecanemab-irmb is approved in the United States, Japan, China, South Korea, Hong Kong, Israel, UAE and Great Britain. The company has also submitted applications for approval of lecanemab in 10 other countries and regions, including the European Union.
MicuRx completes Phase III trial for MRX-4 for injection in China
Renalys Pharma secures Orphan Drug Designation in Japan for sparsentan
Minghui Pharmaceutical reports phase III success for MH004 ointment in atopic dermatitis
CBC Group acquires UCB's mature neurology and allergy business in China
MGI Tech collaborates with Universidad de San Martin de Porres
Allink Biotherapeutics completes USD42m Series A financing round
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children